tirzepatide super obesity bmi 60 and health‐related quality of life in adults with or overweight: Results from the SURMOUNT‐3 phase 3 randomized trial - Gibble - 2025 - Diabetes, Obesity and Metabolism Weight regain after the withdrawal

We suggest it is reasonable for inpatients to restart GLP- 1 RAs when resuming their usual diet (Grade E)

The same dual action GLP-1 and GIP mechanism behind injectable tirzepatide, delivered as a daily oral tablet

Where statements could otherwise be read as independently substantiated facts, attribution language such as "according to the brand," "brand-stated," or "per brand disclosure" identifies them as brand claims not independently substantiated by this publication

Both are administered as once-weekly subcutaneous injections using prefilled pens in the same dose range

Of the 783 patients who started ZEPBOUND at Week 0, 14.4% discontinued treatment before randomization at Week 36, and adverse events were the most common reason for discontinuation (6.8%)